Cellular Immunotherapies: Late Phase and Commercially Available Therapies Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

被引：0

作者：

Ortiz-Maldonado, Valentin ^{[1
]}

Martinez-Cibrian, Nuria ^{[2
]}

Del Campo Balguerias, Gonzalo ^{[3
]}

Espanol-Rego, Marta ^{[4
]}

Navarro, Sergio ^{[4
]}

Brillembourg, Helena ^{[5
]}

Alserawan, Leticia ^{[4
]}

Castella, Maria ^{[4
]}

Benitez-Ribas, Daniel ^{[4
]}

Magnano, Laura ^{[5
]}

Gonzalo Correa, Juan ^{[5
]}

Rivero, Andrea ^{[5
]}

Mozas, Pablo ^{[5
]}

Oliver-Caldes, Aina ^{[6
]}

Gine, Eva ^{[7
]}

Gerardo Rodriguez-Lobato, Luis ^{[5
]}

Martinez-Roca, Alexandra ^{[2
]}

Montoro-Lorite, Mercedes ^{[5
]}

Ayora, Pilar ^{[5
]}

Fernandez de larrea, Carlos ^{[5
]}

Pascal, Mariona ^{[4
]}

Esteve Reyner, Jordi ^{[5
]}

Urbano-Ispizua, Alvaro ^{[5
]}

Juan, Manel ^{[8
]}

Delgado, Julio ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Hosp Clin Barcelona, Barcelona, Spain

[3] Hosp Clin San Carlos, Dept Hematol, Madrid, Spain

[4] Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

[5] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[6] Univ Barcelona, Dept Hematol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[7] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[8] Hosp Clin Barcelona, Dept Immunol, Platform Immunotherapy Clin St Joan Deu, Barcelona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

705

引用

页数：4

共 50 条

[31] High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia
Fried, Shalev
Danylesko, Ivetta
Marcus, Ronit
Itzhaki, Orit
Yerushalmi, Ronit
Shem-Tov, Noga
Sdayoor, Inbal
Shouval, Roni
Jacoby, Elad
Kedmi, Meirav
Nagler, Arnon
Shimoni, Avichai
Avigdor, Abraham
BLOOD, 2023, 142
[32] A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
Srinagesh, Hrishikesh
Jackson, Clayton
Shiraz, Parveen
Jeyakumar, Nikeshan
Hamilton, Mark
Egeler, Emily
Mavroukakis, Sharon
Kuo, Adam
Cancilla, Juancarlos
Sahaf, Bita
Agarwal, Neha
Kanegai, Alyssa
Kramer, Anne Marijn
Arai, Sally
Bharadwaj, Sushma
Dahiya, Saurabh
Hosoya, Hitomi
Johnston, Laura
Kennedy, Vanessa
Liedtke, Michaela
Lowsky, Robert
Mikkilineni, Lekha
Negrin, Robert
Rezvani, Andrew
Sidana, Surbhi
Shizuru, Judith
Smith, Melody
Weng, Wen-Kai
Feldman, Steven
Frank, Matthew J.
Lee, Zachary
Tagliaferri, Mary
Marcondes, A. Mario
Miklos, David
Mackall, Crystal
Muffly, Lori
BLOOD, 2024, 144 (16) : 1689 - 1698
[33] Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
Yoo, Jae Won
BLOOD RESEARCH, 2023, 58 : 20 - 28
[34] Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
Zhu, Haibo
Deng, Haobin
Mu, Juan
Lyu, Cuicui
Jiang, Yanyu
Deng, Qi
ONCOTARGETS AND THERAPY, 2021, 14 : 4023 - 4037
[35] Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma
Abramson, Jeremy S.
Irwin, Kelly E.
Frigault, Matthew J.
Dietrich, Jorg
McGree, Brianne
Jordan, Justin T.
Yee, Andrew J.
Chen, Yi-Bin
Raje, Noopur S.
Barnes, Jeffrey A.
Davis, Benjamin
CANCER, 2019, 125 (21) : 3692 - 3698
[36] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Shah, Bijal D.
Bishop, Michael R.
Oluwole, Olalekan O.
Logan, Aaron C.
Baer, Maria R.
Donnellan, William B.
O'Dwyer, Kristen M.
Holmes, Houston
Arellano, Martha L.
Ghobadi, Armin
Pagel, John M.
Lin, Yi
Cassaday, Ryan D.
Park, Jae H.
Abedi, Mehrdad
Castro, Januario E.
DeAngelo, Daniel J.
Malone, Adriana K.
Mawad, Raya
Schiller, Gary J.
Rossi, John M.
Bot, Adrian
Shen, Tong
Goyal, Lovely
Jain, Rajul K.
Vezan, Remus
Wierda, William G.
BLOOD, 2021, 138 (01) : 11 - 22
[37] Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
Di Blasi, Roberta
Le Gouill, Steven
Bachy, Emmanuel
Cartron, Guillaume
Beauvais, David
Le Bras, Fabien
Gros, Francois-Xavier
Choquet, Sylvain
Bories, Pierre
Feugier, Pierre
Casasnovas, Olivier
Bay, Jacques Olivier
Mohty, Mohamad
Joris, Magalie
Gastinne, Thomas
Sesques, Pierre
Tudesq, Jean-Jacques
Vercellino, Laetitia
Morschhauser, Franck
Gat, Elodie
Broussais, Florence
Houot, Roch
Thieblemont, Catherine
BLOOD, 2022, 140 (24) : 2584 - 2593
[38] Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Zhang, Xian
Yang, Junfang
Shi, Yanze
Song, Dan
Li, Jingjing
Lu, Xin-an
Wu, Fei
Li, Jianqiang
Chen, Dandan
Li, Xiangqun
Xu, Zhongwei
Liu, Shuqiang
Li, Ziyu
Ying, Kui
Wang, Wenya
Lu, Peihua
BLOOD, 2019, 134
[39] A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL)
Davila, Marco L.
Riviere, Isabelle
Wang, Xiuyan
Bartido, Shirley
Stefanski, Jolanta
Taylor, Clare
Olszewska, Malgorzata
Borquez-Ojeda, Oriana
Qu, Jinrong
Wasielewska, Teresa
Frattini, Mark G.
Sadelain, Michel
Brentjens, Renier J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[40] Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
Xu, Qianwen
Shi, Yi
Xue, Lei
An, Furun
Xu, Hui
Liu, Xin
Zhu, Xiaoyu
Sun, Zimin
Zhai, Zhimin
Wang, Xingbing
CELL TRANSPLANTATION, 2023, 32

← 1 2 3 4 5 →